SecBot SecBot
SECBOTREPLAY Home › Report › IBRX

IBRX · ImmunityBio reported record Q2 2026 net product revenue of $50.7M, up…

ImmunityBio, Inc. · 8-K filed Aug 4, 2026 at 07:36 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Aug 4, 2026 at 07:36 ET

ImmunityBio reported record Q2 2026 net product revenue of $50.7M, up 92% YoY and 15% sequentially, marking the eighth consecutive quarter of growth. The FDA accepted the sBLA for ANKTIVA in BCG-unresponsive NMIBC with a PDUFA date of Jan 6, 2027.

  • Q2 2026 net product revenue of $50.7M, up 92% YoY and 15% sequentially from Q1 2026.
  • First-half 2026 net product revenue of $94.8M, up 121% YoY.
  • FDA accepted sBLA for ANKTIVA in BCG-unresponsive NMIBC with papillary-only disease; PDUFA date Jan 6, 2027.
  • GAAP net loss attributable to common stockholders was $230.4M in Q2 2026 vs $92.6M in Q2 2025.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access